Navigation Links
Human Gene Therapy expands with robust new methods journal
Date:9/13/2011

New Rochelle, NY, September 13, 2011Mary Ann Liebert, Inc. announces the launch of a journal expansion, Human Gene Therapy Methods, to complement the flagship publication Human Gene Therapy. HGT Methods, which is officially Part B of Human Gene Therapy, is dedicated to publishing technological advances in cell and gene therapy that promote the development of gene therapy products into successful therapeutics. While Methods has always been a key element of the flagship journal, HGT Methods breaks new ground as the first publication to exclusively focus on the applications of gene therapy to product testing and development. HGT Methods will publish bimonthly and will premier in January 2012, with accepted articles appearing online ahead of print beginning in November 2011. Editor-in-Chief, James M. Wilson, MD, PhD, introduces this exciting journal expansion in this month's Editorial.

The field of gene therapy is rapidly evolving and holds great promise for its applications to treating human diseases, yet no product has been commercialized. Better methods are needed to evaluate the outcome of gene transfer technologies which are just entering the clinic. Likewise, standards for producing and characterizing products for distribution to patients have yet to be determined. HGT Methods answers the growing need for a central forum for nurturing, promoting, and advancing new technologies and methods that will ultimately pave the way for product development.

The existing leadership team of Human Gene Therapy, together with the newly appointed HGT Methods Editor, Thierry Vanden Driessche, PhD, will be responsible for the development and management of this new Journal.

"Gene therapy was predicted to revolutionize the practice of medicine," according to James M. Wilson, MD, PhD, Editor-in-Chief and Director of the Gene Therapy Program, Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia. "After 30 years of research and recent successes in Phase I clinical trials, it appears the revolution is upon us. For this revolution to realize its true potential we need to translate proof-of-concept studies in small human trials to commercialized products that become standard clinical practice. Human Gene Therapy Methods will be the venue for publishing the technological advances necessary for gene therapy products to be developed as successful therapeutics."


'/>"/>

Contact: Vicki Cohn
vcohn@liebertpub.com
914-740-2100
Mary Ann Liebert, Inc./Genetic Engineering News
Source:Eurekalert  

Related biology news :

1. Swiss Institute of Bioinformatics celebrates 10th birthday by presenting major gifts to human health
2. Scientists identify novel inhibitor of human microRNA
3. During exercise, the human brain shifts into high gear on alternative energy
4. Complete Genomics launches, becomes worlds first large-scale human genome sequencing company
5. Research shows Brazilian acai berry antioxidants absorbed by human body
6. Study: Bird diversity lessens human exposure to West Nile Virus
7. Human Microbiome Project awards funds for technology development, data analysis and ethical research
8. TheVisualMD.com launches new animated 3-D views of human body in action
9. Gene with probable role in human susceptibility to pulmonary tuberculosis identified
10. The American Society of Human Genetics hosts 58th Annual Meeting in Philadelphia
11. Genetic based human diseases are an ancient evolutionary legacy
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Human Gene Therapy expands with robust new methods journal
(Date:2/8/2017)... , Feb. 7, 2017 The biometrics ... by the confluence of organizations, desires to better ... knowledge-based systems (password and challenge questions), biometrics is ... government systems. The market is driven by use ... between consumer and enterprise uses cases, with consumer-facing ...
(Date:2/7/2017)... 7, 2017 Ipsidy Inc. ( ... [OTC: IDGS], ("Ipsidy" or the "Company") a provider of ... services, is pleased to announce the following changes as ... Effective January 31, 2017, Philip D. Beck ... and President.  An experienced payment industry professional and public ...
(Date:2/2/2017)... 2017   TapImmune, Inc. (NASDAQ: ... in the development of innovative peptide and gene-based ... and metastatic disease, announced today it has successfully ... a second clinical lot of TPIV 200, the ... The manufactured vaccine product will be used to ...
Breaking Biology News(10 mins):
(Date:2/20/2017)... ... February 20, 2017 , ... PuraCath Medical, ... with peritoneal dialysis, announced today that it has published the result of its ... Peritoneal Dialysis International (PDI), the official Journal of the International Society for ...
(Date:2/20/2017)... 20, 2017  Atrius Health and IBM (NYSE: ... agreement to develop a cloud based service designed ... holistic view of the multiple influences on an ... could be designed to support shared decision making ... innovative nonprofit healthcare organization with 875 physicians caring ...
(Date:2/18/2017)... Heights, IL (PRWEB) , ... February 17, 2017 ... ... for Blood and Marrow Transplantation (ASBMT) and the Center for International Blood & ... Palms Convention Center in Orlando, Fla. , The combined scientific sessions ...
(Date:2/17/2017)... According to a new ... Service), Type (Safety, Efficacy, Validation), Disease Indication (Cancer, ... Development, Disease-Risk) - Global Forecast to 2021" published ... USD 53.34 Billion by 2021 from USD 27.95 ... 13.8% during the forecast period (2016-2021). ...
Breaking Biology Technology: